TY - JOUR AB - Cancer stem cells in breast cancer migrating to the bone marrow may cause future metastasis, particularly during periods of decreased immunity. Natural killer (NK) cells have a role in immune surveillance and are able to target cancer stem cells. The present study reported a case in which NK cell‑based autologous immune enhancement therapy was used combined with conventional treatments in a patient with stage IIIA breast cancer, yielding >28 months of disease‑free survival. However, there was a gradual decline in the in vitro expansion of NK cells with subsequent chemotherapeutic treatments. As this NK cell decline following chemotherapy may contribute to cancer cell immune evasion and future metastasis; modifying current cancer therapies in order to avoid potentially compromising the immune system may lead to improved treatment outcomes. AD - RUMA Biotherapy and Research Centre, Moolakulam, Puducherry‑605010, India Biotherapy Institute of Japan, Tokyo 135‑0051, Japan The Mary‑Yoshio Translational Hexagon (MYTH), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai, Tamil Nadu 600034, India Chennai Meenakshi Multispeciality Hospital Limited, Chennai, Tamil Nadu 600004, India The Fujio‑Eiji Academic Terrain (FEAT), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai, Tamil Nadu 600034, India Department of Surgery, Υamanashi University School of Medicine, Chuo, Yamanashi 409‑3898, Japan AU - Chidambaram,Ranganathan AU - Terunuma,Hiroshi AU - Balamurugan,Madasamy AU - Dedeepiya,Vidyasagar ,Devaprasad AU - Sumana,Premkumar AU - Senthilkumar,Rajappa AU - Rajmohan,Mathaiyan AU - Karthick,Ramalingam AU - Preethy,Senthilkumar AU - Abraham,Samuel ,J.K. DA - 2017/09/01 DO - 10.3892/mco.2017.1333 EP - 497 IS - 3 JO - Mol Clin Oncol KW - breast cancer autologous immune enhancement therapy natural killer cells cancer stem cells immune loopholes PY - 2017 SN - 2049-9450 2049-9469 SP - 493 ST - Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report T2 - Molecular and Clinical Oncology TI - Cell‑based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report UR - https://doi.org/10.3892/mco.2017.1333 VL - 7 ER -